Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

BACKGROUND: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. CASE PRESENTATION: We herein report th...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Marino, Pietro, Mannetta, Gianluca, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, Natoli, Clara, De Tursi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083626/
https://www.ncbi.nlm.nih.gov/pubmed/32214855
http://dx.doi.org/10.2147/IMCRJ.S229080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083626/
https://www.ncbi.nlm.nih.gov/pubmed/32214855
http://dx.doi.org/10.2147/IMCRJ.S229080

Ejemplares similares